AGTC is open to clinical and manufacturing partnership.
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by single genes mutations, that significantly affect visual function. We also have IND stage programs in ophthalmology, CNS, and otology.
Brands: AGTC has a robust pipeline of products in ophthalmology, CNS, and otology with two late stage clinical trials in X-Linked Retinitis Pigmentosa and Achromatopsia.